Treatment of Parkinson's disease.
Identifieur interne : 000294 ( Ncbi/Merge ); précédent : 000293; suivant : 000295Treatment of Parkinson's disease.
Auteurs : W R Wayne Martin [Canada] ; Marguerite WielerSource :
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [ 0317-1671 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dyskinesias (etiology), Holistic Health, Humans, Levodopa (adverse effects), Musculoskeletal Manipulations, Neuroprotective Agents (therapeutic use), Occupational Therapy, Parkinson Disease (nursing), Parkinson Disease (rehabilitation), Parkinson Disease (therapy), Speech Therapy.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Neuroprotective Agents.
- etiology : Dyskinesias.
- nursing : Parkinson Disease.
- rehabilitation : Parkinson Disease.
- therapy : Parkinson Disease.
- Holistic Health, Humans, Musculoskeletal Manipulations, Occupational Therapy, Speech Therapy.
Abstract
Parkinson's disease is a progressive neurodegenerative disorder that demands a holistic approach to treatment. Both pharmacologic and nonpharmacologic interventions play an important role in the comprehensive management of this disorder. While levodopa remains the single most effective medication for symptomatic treatment, dopamine agonists are playing an increasingly important role. Motor complications of dopaminergic therapy are a significant issue, particularly in patients with more advanced disease who have been on levodopa for several years. All therapeutic interventions must be tailored to the individual and modified as the disease progresses, with the goal of minimizing significant functional disability as much as possible.
PubMed: 12691474
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001446
- to stream PubMed, to step Curation: 001446
- to stream PubMed, to step Checkpoint: 001446
Links to Exploration step
pubmed:12691474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of Parkinson's disease.</title><author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W R Wayne" last="Martin">W R Wayne Martin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Alberta, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12691474</idno><idno type="pmid">12691474</idno><idno type="wicri:Area/PubMed/Corpus">001446</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001446</idno><idno type="wicri:Area/PubMed/Curation">001446</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001446</idno><idno type="wicri:Area/PubMed/Checkpoint">001446</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001446</idno><idno type="wicri:Area/Ncbi/Merge">000294</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of Parkinson's disease.</title><author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W R Wayne" last="Martin">W R Wayne Martin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Alberta, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name></author></analytic><series><title level="j">The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</title><idno type="ISSN">0317-1671</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dyskinesias (etiology)</term><term>Holistic Health</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Musculoskeletal Manipulations</term><term>Neuroprotective Agents (therapeutic use)</term><term>Occupational Therapy</term><term>Parkinson Disease (nursing)</term><term>Parkinson Disease (rehabilitation)</term><term>Parkinson Disease (therapy)</term><term>Speech Therapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="nursing" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Holistic Health</term><term>Humans</term><term>Musculoskeletal Manipulations</term><term>Occupational Therapy</term><term>Speech Therapy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease is a progressive neurodegenerative disorder that demands a holistic approach to treatment. Both pharmacologic and nonpharmacologic interventions play an important role in the comprehensive management of this disorder. While levodopa remains the single most effective medication for symptomatic treatment, dopamine agonists are playing an increasingly important role. Motor complications of dopaminergic therapy are a significant issue, particularly in patients with more advanced disease who have been on levodopa for several years. All therapeutic interventions must be tailored to the individual and modified as the disease progresses, with the goal of minimizing significant functional disability as much as possible.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12691474</PMID><DateCreated><Year>2003</Year><Month>04</Month><Day>14</Day></DateCreated><DateCompleted><Year>2003</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0317-1671</ISSN><JournalIssue CitedMedium="Print"><Volume>30 Suppl 1</Volume><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</Title><ISOAbbreviation>Can J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>S27-33</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease is a progressive neurodegenerative disorder that demands a holistic approach to treatment. Both pharmacologic and nonpharmacologic interventions play an important role in the comprehensive management of this disorder. While levodopa remains the single most effective medication for symptomatic treatment, dopamine agonists are playing an increasingly important role. Motor complications of dopaminergic therapy are a significant issue, particularly in patients with more advanced disease who have been on levodopa for several years. All therapeutic interventions must be tailored to the individual and modified as the disease progresses, with the goal of minimizing significant functional disability as much as possible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>W R Wayne</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieler</LastName><ForeName>Marguerite</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Neurol Sci</MedlineTA><NlmUniqueID>0415227</NlmUniqueID><ISSNLinking>0317-1671</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006694" MajorTopicYN="N">Holistic Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026201" MajorTopicYN="N">Musculoskeletal Manipulations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009788" MajorTopicYN="N">Occupational Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013070" MajorTopicYN="N">Speech Therapy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>64</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12691474</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name></noCountry><country name="Canada"><noRegion><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W R Wayne" last="Martin">W R Wayne Martin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000294 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000294 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:12691474
|texte= Treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:12691474" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |